The 60-kDa Phosphotyrosine Protein in Insulin-treated Adipocytes Is a New Member of the Insulin Receptor Substrate Family*

(Received for publication, January 13, 1997)

Brian E. Lavan Dagger , William S. Lane § and Gustav E. Lienhard

From the Department of Biochemistry, Dartmouth Medical School, Hanover, New Hampshire 03755 and the § Harvard Microchemistry Facility, Department of Molecular and Cellular Biology, Harvard University, Cambridge, Massachusetts 02318

ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
FOOTNOTES
ACKNOWLEDGEMENTS
REFERENCES


ABSTRACT

A 60-kDa protein that undergoes rapid tyrosine phosphorylation in response to insulin and then binds phosphatidylinositol 3-kinase has been previously described in adipocytes and hepatoma cells. We have isolated this protein, referred to as pp60, from rat adipocytes, obtained the sequences of tryptic peptides, and cloned its cDNA. The predicted amino acid sequence of pp60 reveals that it contains an N-terminal pleckstrin homology domain, followed by a phosphotyrosine binding domain, followed by a group of likely tyrosine phosphorylation sites, four of which are in the YXXM motif that binds to the SH2 domains of phosphatidylinositol 3-kinase. The overall architecture of pp60 is thus the same as that of insulin receptor substrates 1 and 2 (IRS-1 and IRS-2), and furthermore both the pleckstrin homology and phosphotyrosine binding domains are highly homologous (about 50% identical amino acids) to these domains in both IRS-1 and IRS-2. Thus, pp60 is a new member of the IRS family, which we have designated IRS-3.


INTRODUCTION

The insulin receptor is a tyrosine kinase that is activated upon insulin binding. Signaling from this receptor proceeds primarily by its tyrosine phosphorylation of substrate proteins, which then act as docking proteins for one or more SH21 domain-containing proteins. Docking of these proteins in turn activates specific signal transduction pathways. The substrate docking proteins that have been molecularly characterized to date are the closely related IRS-1 and IRS-2 as well as SHC (reviewed in Refs. 1 and 2). One protein of this type that hitherto has not been cloned is a 60-kDa protein described in rat adipocytes and rat hepatoma cells. This 60-kDa protein, referred to as pp60, is rapidly tyrosine phosphorylated in response to insulin and in this form associates with the 85-kDa regulatory subunit of PI 3-kinase (3, 4). The interaction between these two proteins involves the binding of Tyr(P) to either or both of the SH2 domains of the 85-kDa subunit, because each SH2 domain by itself binds the Tyr(P) form of pp60 (3, 4). In the present study, we have isolated pp60 from insulin-treated rat adipocytes and then cloned its cDNA. The predicted amino acid sequence shows that pp60 is a new member of the IRS family.


EXPERIMENTAL PROCEDURES

Preparation of Affinity Matrix

GST itself and the GST fusion protein with the N-terminal SH2 domain of the 85-kDa subunit of PI 3-kinase (GST-NSH2) were prepared as described (5). These were covalently attached via sulfhydryl groups on the GST (the SH2 domain itself has no sulfhydryl groups) to activated thiopropyl Sepharose 6B beads (Sigma). The beads with coupled GST (1.3 mg/ml) or GST-NSH2 (1.8 mg/ml) were placed in columns, washed with 10 volumes of 5 mM dithiothreitol in 120 mM Tris-HCl, 1 mM EDTA, pH 6.8, to cleave the remaining 2-pyridyl disulfide, and then washed with 30 volumes of 5 mM N-ethylmaleimide in this buffer to block the free sulfhydryl groups. Protein not covalently bound to the beads was released with 25 volumes of 4% SDS, 2 mM N-ethylmaleimide, 100 mM Tris-HCl, 1 mM EDTA, 10% glycerol, pH 6.8. Finally, the columns were washed extensively with 150 mM NaCl, 10 mM sodium phosphate, pH 7.4. The SDS treatment released only about 10% of protein, and subsequently the GST-NSH2 exhibited full activity in binding pp60.

Isolation of pp60 and Sequencing of Peptides

Rat adipocytes were prepared and treated with insulin as described (3). The cells were lysed in hot SDS buffer, the lysate was diluted with a buffer containing nonionic detergent, and particulate matter removed by centrifugation and filtration, exactly as described in Ref. 3, with the exception that the nonionic detergent was nonylethylene glycol dodecyl ether (ThesitTM from Boehringer Mannheim) rather than octylethylene glycol dodecyl ether. The cell extract (350 ml) from the adipocytes of 150 rats was passed at 0.14 ml/min through a 1.5-ml column of immobilized GST and then through a 0.2-ml column of immobilized GST-NSH2. Once the extract was applied, the GST column was disconnected, and a 0.2-ml portion of it was treated exactly as the GST-NSH2 column to serve as the control. The columns were washed with 20 ml of 1% Thesit in 20 mM Tris-HCl, 150 mM NaCl, 1 mM sodium vanadate, pH 7.4, with protease inhibitors (2 µg/ml aprotinin, 2 µM leupeptin, 0.2 nM pepstatin A) and then with 20 ml of 0.1% Thesit in the same buffer. The beads from each column (about 0.2 ml) were transferred to low protein-binding microfuge tubes, and a hole was pierced in the bottom of each using a 26 gauge needle. Adherent liquid was removed by centrifuging briefly with each tube inside a second tube. Bound proteins were then eluted from the beads in an SDS buffer (4% SDS, 1 mM EDTA, 1 mM sodium vanadate, 10% glycerol, 100 mM Tris-HCl, pH 6.8, with the protease inhibitors given above) by the same method. Beads were eluted successively with two 90-µl portions of SDS buffer, followed by two 180-µl portions. The eluates are referred to in order of elution as P (combined 90-µl eluates), P1 and P2 from the GST-NSH2 and similarly, G, G1, and G2 from the GST. To estimate the yield of pp60, samples containing the original extract, the depleted extract, and the eluate fractions were quantitatively immunoblotted for Tyr(P) as described (3). Approximately 90% of the purified pp60 was in fraction P, with most of the remainder in fraction P1.

Eluate fractions P and G were each separated on single lanes of a 5-12% acrylamide gradient gel. The pp60 in the lane with fraction P was detected by copper staining for protein (Bio-Rad); this area along with the corresponding area from the lane with G was excised. After S-carboxyamidomethylation in a gel, the bands were subjected to tryptic digestion in a gel as described in Ref. 6 without the addition of 0.02% Tween. The resulting peptide mixture was separated by microbore high performance liquid chromatography using a Zorbax C18 1.0 mm by 150-mm reverse-phase column on a Hewlett-Packard 1090 HPLC/1040 diode array detector. Optimum fractions were chosen based on differential UV absorbance at 205, 277, and 292 nm, and the sequences of eight peptides unique to the P fraction were determined by automated Edman degradation on an Applied Biosystems 494A or 477A sequencer. The average initial amino acid yield for the peptides sequenced was 820 ± 310 fmol. Strategies for peak selection, reverse-phase separation, and Edman microsequencing have been previously described (7). Complementary peptide sequence information was obtained on 10% of the digest mixture by collisionally induced dissociation using microcapillary HPLC electrospray ionization/tandem mass spectrometry on a Finnigan TSQ7000 triple quadrupole mass spectrometer (8).

pp60 cDNA

Total RNA was obtained from rat adipocytes using the Trizol reagent (Life Technologies), and mRNA was subsequently purified from it using the Fast-Track kit (Invitrogen). The adipocytes of 24 rats yielded approximately 4 µg of twice purified mRNA. An oligo(dT) primed cDNA library of the Marathon ReadyTM type was prepared for us from this mRNA by Clontech. Tryptic peptide g (see Fig. 1B) served as the basis for the design of a mixed sense oligonucleotide containing deoxyinosine (I) at positions of high degeneracy (5'-TTYYTICCIGGICCIYTITAYTAYGARTT-3': where Y is T or C and R is A or G). 3' RACE was performed with the Marathon Ready cDNA using this primer (20 µM) and the AP1 primer (2 µM) of the Marathon Ready kit, according to the manufacturer's instructions. A major 700-bp product was obtained that was reamplified and then gel purified. After filling the 5' and 3' ends with Klenow DNA polymerase, the piece was digested with NotI (a site introduced during cDNA synthesis) and cloned into NotI/EcoRV digested pBluescript II (SK-) (Stratagene). The insert was sequenced (nt 1409-1969, see Fig. 2) and was found to encode tryptic peptide h.


Fig. 1. Purification of pp60 from insulin-stimulated rat adipocytes and sequences of tryptic peptides. A, pp60 was purified as described under "Experimental Procedures" and "Results and Discussion." Samples of the fractions eluted with SDS from the GST-NSH2 column (P1 and P2) or from the control GST column (G1 and G2) were separated on a 5-12% polyacrylamide gradient gel, transferred to nitrocellulose, and either immunoblotted for Tyr(P) (lanes 1-4) or stained for protein with colloidal gold (lanes 5-8). Lanes 1-4 contained 0.5% of each SDS eluate fraction, and lanes 5-8 contained the remainder. Molecular mass standard proteins were run on lanes 9-11 at several loads (ng of each shown). B, the amino acid sequences of eight tryptic peptides (designated a-h) from pp60 are given. Uppercase and lowercase one-letter abbreviations for the amino acids indicate assignments made with high and low confidence, respectively. x designates a position for which no assignment could be made.
[View Larger Version of this Image (46K GIF file)]



Fig. 2. Nucleotide and amino acid sequence of rat pp60. Sequences within the amino acid sequence that correspond to the sequences of the tryptic peptides (Fig. 1B) are underlined and labeled with the small letter designation of the peptide. All peptide sequences matched exactly with the predicted ones. The in-frame stop codon (TAG) upstream of the initiation codon, the Kozak consensus sequence (GGAC), and the polyadenylation signal (AATAAA) are underlined. The 3' RACE product contained poly(A) beyond nt 1969. Because the nucleotide sequence of pp60 was obtained by direct sequencing of PCR products, an allelic form of the protein was identified: equal signals for G and C at nt 194 (denoted by +) were repeatedly found; thus amino acid 2 can be either K, as shown, or N. The location of the putative 170-bp intron (see "Experimental Procedures") between nt 618 and 619 is marked by an asterisk.
[View Larger Version of this Image (46K GIF file)]


The 5' end of the cDNA was obtained by 5' RACE with the Marathon-Ready cDNA and a combination of the AP1 primer and an antisense primer derived from the 3' RACE product (nt 1565-1589). Two major PCR products of approximately 1600 and 1800 bp were generated in the initial amplification and gel purified as a mixture. Reamplification of the mixture with nested primers (AP2 of the Marathon-Ready kit and an upstream antisense primer (nt 1531-1556)) again generated a mixture of two PCR products. This mixture of PCR products was directly sequenced from its 3' end and found to be identical from nt 619 to 1530. Upstream of nt 619 the sequence was a mixture, indicating that the two PCR products diverged at this point. To obtain sequence upstream of nt 619, the mixture of PCR products was subcloned into pBluescript II (SK-) and parts of the inserts from some clones were sequenced. Primers based upon this sequence were then used to sequence directly the 5' end of the mixture of the two PCR products. These gave a single sequence at the most 5' end (nt 1-618) and a mixture of sequences downstream of nt 618; this indicated the presence of an intervening sequence of about 200 bp between nt 618 and 619 in the larger PCR product. To confirm the cDNA sequence, overlapping PCR fragments were generated from the Marathon Ready cDNA with appropriate primers (encompassing nt 97-559, 359-689, 640-1265, 1211-1589, and 1333-1925). As expected, in the case of amplification of the nt 359-689 fragment, a second fragment of 170 bp larger size was also obtained. Each of the PCR products was gel purified, and both strands were directly sequenced. The 170-bp sequence that was present in only some of the cDNA molecules is probably an unspliced intron, because its very 5' and 3' sequences are those for splice junctions (GT and AG, respectively) and because it contains an in-frame stop codon. DNA sequencing was performed on the Applied Biosystems 373 DNA sequencing system using the Perkin-Elmer DNA sequencing kit; data were analyzed with the Applied Biosystems software. Homology searches were performed with the BLAST program (25).


RESULTS AND DISCUSSION

Purification of pp60

The method for the purification of pp60 was based on our previous finding that pp60 is efficiently adsorbed from extracts of insulin-treated adipocytes by the N-terminal SH2 domain of the 85-kDa subunit of PI 3-kinase as a GST fusion protein (3). An extract of insulin-treated adipocytes from 150 rats was passed sequentially through a column of immobilized GST alone and then through a column containing the GST-NSH2 fusion protein. After the adsorption step, the columns were separated, each was washed, and adsorbed proteins were eluted with SDS. Fig. 1A (lanes 1-4) shows the eluted Tyr(P) proteins as detected by anti-Tyr(P) immunoblotting. The major Tyr(P) proteins had mobilities corresponding to those expected for pp60 and IRS-1. Smaller amounts of Tyr(P) proteins at approximately 97 and 145 kDa were also present. The 97-kDa protein is most likely the beta  subunit of the insulin receptor, which is known to bind to the N-terminal SH2 domain of PI 3-kinase (9); the identity of the 145-kDa protein is unknown. There was specific binding to the GST-NSH2 column; no Tyr(P) proteins were present in the eluate from the GST column (compare lane 1 with 3). Protein staining with colloidal gold showed that two major proteins were eluted specifically from the GST-NSH2 column (Fig. 1A, lanes 5-8); these co-migrated with the Tyr(P) forms of pp60 and IRS-1. From quantitative immunoblotting of the adipocyte lysate and the SDS eluate fractions of the column for Tyr(P) (data not shown), we determined that approximately 30% of the Tyr(P) form of pp60 was recovered in the purification. In addition, from this data and that in Fig. 1A, we estimate that approximately 500 ng (8 pmol) of pp60 were isolated from the adipocytes of 150 rats.

To obtain peptides from pp60, the bulk of the SDS eluate from the GST-NSH2 column (about 90%, with the remainder used for the analyses described above) was run in a single lane on a gradient gel, and the gel slice containing pp60 was treated with trypsin. Tryptic peptides were isolated by HPLC, and the sequences of eight peptides were determined (Fig. 1B). A search of the data base using the BLAST program revealed no significant matches with sequences in known proteins.

cDNA Encoding pp60

Initially a PCR product encoding the 3' end of pp60 was generated in a 3' RACE reaction using a degenerate primer based upon the sequence of peptide g and a Marathon-Ready cDNA library from rat adipocytes. Subsequently, the 5' end of the pp60 cDNA was obtained by a 5' RACE procedure. The nucleotide sequence and predicted amino acid sequence of pp60 are presented in Fig. 2. An open reading frame extending from nt 189 to 1673 encodes a 494-amino acid polypeptide that contains all eight of the sequences found for the pp60 tryptic peptides. It is virtually certain that the ATG codon at nt 189-191 initiates translation, because upstream there is no in-frame ATG codon between it and an in-frame stop codon at nt 123-125, because the next downstream ATG (nt 615-617) is beyond the PH domain (see below), and because the sequence just upstream of nt 189-191 conforms to the rat Kozak consensus sequence for translation initiation (10). The predicted molecular mass of pp60 is 55.3 kDa, a value that is smaller than the size of approximately 60 kDa for the Tyr(P) form estimated by SDS gel electrophoresis. The explanation for this difference most likely is an aberrantly low mobility on electrophoresis, which is frequently the case for phosphorylated proteins.

Several types of evidence establish that the predicted protein is the 60-kDa protein that undergoes tyrosine phosphorylation in response to insulin. First, as noted above, the isolation of the cloned protein was based on a known binding property of pp60. Second, as described below, the structure of the protein is that expected for a substrate of the insulin receptor; the predicted sequence contains, as expected, several potential PI 3-kinase binding motifs. Third, we have prepared affinity purified rabbit antibodies against the C-terminal peptide (14 amino acids) of the predicted protein and shown that these react with pp60. The tyrosine phosphorylated form of pp60 was isolated from a lysate of insulin-treated adipocytes by adsorption with GST-NSH2 or with antibodies against Tyr(P), as described in Ref. 3. Immunoblotting of each adsorbate with the antibodies against the C terminus detected only a 60-kDa protein. When this experiment was performed with a lysate of basal adipocytes, no protein was detected (data not shown).

Domains and Tyr(P) Motifs in pp60

The amino acid sequence of pp60 was compared with the protein data base using the BLAST P program and also was examined for potential sites of tyrosine phosphorylation. This revealed that pp60 contains in the following order from its N terminus: a PH domain that is highly homologous to the PH domain in IRS-1 and IRS-2, a PTB domain that is highly homologous to the PTB domain in IRS-1 and IRS-2, and, distributed over the C-terminal third of the protein, a number of likely tyrosine phosphorylation sites in motifs that can bind SH2 domain-containing proteins (Fig. 3 and see below). The architecture of pp60 is strikingly similar to that of IRS-1 and IRS-2. Although the latter two proteins are larger (1231 and 1321 amino acids, respectively), each contains an N-terminal PH domain, followed by a PTB domain, followed by a group of tyrosine phosphorylation sites at which a variety of SH2-domain signaling proteins dock (2, 11). Thus, pp60 is a new member of the IRS family, and henceforth we refer to it as IRS-3.


Fig. 3. Structure of IRS-3 (pp60) and homology with IRS-1/2. A, the organization of IRS-3, showing the PH and PTB domains and the potential sites of tyrosine phosphorylation. The latter are those tyrosine residues that have one or more acidic residues within the immediate five upstream amino acids (24). B, the PH and PTB domains from rat IRS-1, rat IRS-2, and rat IRS-3 were aligned with the PILEUP program (GCG Wisconsin). Identical amino acid residues at a position are on a black background, and conserved amino acid residues are on a gray background. The percentage values at the end of each sequence are the percentage of identical amino acids in a pairwise comparison of each to the IRS-3 sequence. The PH and PTB domains of IRS-1 and IRS-2 are 69 and 75% identical to each other, respectively (11). The two conserved Arg residues of the IRS-1 PTB domain that contact the Tyr(P) of the bound peptide similar in sequence to that around Tyr960 of the insulin receptor are marked with an asterisk.
[View Larger Version of this Image (28K GIF file)]


The PH domain of IRS-3 consists of 100 amino acids (residues 32-131) and exhibits 50 and 45% identity with this domain in IRS-1 and IRS-2, respectively (Fig. 3B). This high degree of homology is notable, because the sequences of PH domains generally show a great deal of variation (12) and suggests that there is a common function for the PH domain in the three IRSs. In this regard, the PH domain of IRS-1 is necessary for its efficient in vivo tyrosine phosphorylation by the insulin receptor, although it does not appear to interact directly with the receptor (13-15).

The PTB domain in IRS-3 consists of 115 amino acids (residues 160-274) and exhibits 48 and 53% identity with this domain in IRS-1 and IRS-2, respectively (Fig. 3B). The IRS PTB domain was originally identified as a region of approximately 160 amino acids that is highly homologous in IRS-1 and IRS-2 and that binds to the tyrosine phosphorylated insulin receptor and to phosphopeptides mimicking the sequence surrounding Tyr960 in the receptor (11, 16). More recently, the minimal PTB domain in IRS-1 has been delineated both functionally by deletion analysis and structurally by x-ray crystallography and has been found to be somewhat smaller, extending over 105 amino acids (residues 161-265 in human IRS-1, corresponding to residues 156-260 in rat IRS-1) (17). The region of homology between IRS-1 (residues 157-255) and IRS-3 corresponds almost exactly with this minimal PTB domain; the immediately flanking sequences in IRS-1 and IRS-2 show little homology with IRS-3. The crystal structure of the IRS-1 PTB domain complexed with a 9-residue Tyr(P) peptide similar to the sequence surrounding Tyr960 in the insulin receptor has been determined (17). Remarkably, 14 of the 19 amino acids in IRS-1 that interact with the bound peptide (Fig. 6 of Ref. 17) are identical in IRS-3, including the two arginines whose guanidinium groups contact the phosphate of the Tyr(P) residue; the remaining five differences are conservative substitutions. This suggests that IRS-3 will also be found to bind via its PTB domain to the activated insulin receptor by association with the segment containing Tyr(P)960.

Outside of the PH and PTB domains there are no regions of extended homology between IRS-3 and IRS-1/2. Although IRS-1 and IRS-2 contain a region just downstream of the PTB domain referred to as the SAIN domain, which participates in the interaction with the insulin receptor, and IRS-2 also contains a domain even further downstream (residues 591-733) that also interacts with the receptor (15, 18-20), neither of these are present in IRS-3.

Several of the potential tyrosine phosphorylation sites in IRS-3 lie within motifs that conform to the established recognition specificities of SH2 domains (21, 22). Most notably, there are four YXXM motifs (Tyr343, Tyr352, Tyr362, and Tyr392); this is the motif to which each SH2 domain of the PI 3-kinase 85-kDa subunit binds. Given the strong association of the Tyr(P) form of IRS-3 with both SH2 domains, one or more of these sites is almost certainly phosphorylated in vivo. The occurrence of a linear array of four YXXM motifs suggests that tandem motifs are phosphorylated and then bind simultaneously to the two SH2 domains on the 85-kDa subunit; such a bidentate interaction has been shown to result in very high affinity binding (23). Among the other potential tyrosine phosphorylation sites of IRS-3, there is one (Tyr321) that would be expected to bind to the SH2 domain of Grb2, the adaptor for SOS (the GDP-releasing factor for Ras), and another (Tyr466) that could bind to N-terminal SH2 domain of either the Tyr(P) phosphatase SHP2 or phospholipase Cgamma . It remains to be determined whether these or other SH2 domain proteins are associated with the Tyr(P) form of IRS-3. Because the Tyr(P) forms of IRS-1 and IRS-2 function as docking/effector proteins for PI 3-kinase, Grb2, and SHP2 (2), the similarity of IRS-3 with IRS-1/2 extends to at least one and probably several interactions with SH2 domain proteins.

Implications

The rapid tyrosine phosphorylation of IRS-3 in response to insulin and the identification of it as a member of the IRS family strongly indicates that it is a substrate for the insulin receptor. However, this remains to be demonstrated. Besides the insulin receptor, a variety of other receptors, including the related receptor for insulin-like growth factor I, signal through tyrosine phosphorylation of IRS-1/2 (1, 2). Thus, IRS-3 may also participate in signal transduction from other receptors. A major challenge now is to elucidate the role that each IRS plays in insulin action.


FOOTNOTES

*   This work was supported by National Institutes of Health Grant DK 42816.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

The nucleotide sequence(s) reported in this paper has been submitted to the GenBankTM/EMBL Data Bank with accession number(s) U93880[GenBank].


Dagger    To whom correspondence should be addressed. Tel.: 603-650-1615; Fax: 603-650-1128.
1   The abbreviations used are: SH2, Src homology 2; GST, glutathione S-transferase; GST-NSH2, GST fusion protein with N-terminal SH2 domain of phosphatidylinositol 3-kinase; HPLC, high performance liquid chromatography; IRS, insulin receptor substrate; PCR, polymerase chain reaction; PH, pleckstrin homology; PI, phosphatidylinositol; PTB, phosphotyrosine binding; RACE, rapid amplification of cDNA ends; bp, base pair(s); nt, nucleotide(s).

ACKNOWLEDGEMENTS

We thank Susanna Keller for guidance in recombinant DNA methods and critical reading of the manuscript, Nicholas Morris for preparation of the mRNA, Renee Robinson, John Neveu, and Terri Addona for expertise in the HPLC, peptide sequencing, and mass spectrometry, respectively, and Mary Harrington for expert secretarial assistance.


REFERENCES

  1. White, M. F., and Kahn, C. R. (1994) J. Biol. Chem. 269, 1-4 [Free Full Text]
  2. Waters, S. B., and Pessin, J. E. (1996) Trends Cell Biol. 6, 1-4 [CrossRef]
  3. Lavan, B. E., and Lienhard, G. E. (1993) J. Biol. Chem. 268, 5921-5928 [Abstract/Free Full Text]
  4. Milarski, K. L., Lazar, D. F., Wiese, R. J., and Saltiel, A. R. (1995) Biochem. J. 308, 579-583 [Medline] [Order article via Infotrieve]
  5. Lavan, B. E., Kuhné, M. R., Garner, C. W., Anderson, D., Reedijk, M., Pawson, T., and Lienhard, G. E. (1992) J. Biol. Chem. 267, 11631-11636 [Abstract/Free Full Text]
  6. Hellman, U., Wernstedt, C., Góñez, J., and Heldin, C.-H. (1995) Anal. Biochem. 191, 332-336
  7. Lane, W. S., Galat, A., Harding, M. W., and Schreiber, S. L. (1991) J. Protein Chem. 10, 151-160 [Medline] [Order article via Infotrieve]
  8. Hunt, D. F., Henderson, R. A., Shabanowitz, J., Sakaguchi, K., Michel, K., Sevilir, N., Cox, A., Appella, E., and Engelhard, V. H. (1992) Science 255, 1261-1263 [Medline] [Order article via Infotrieve]
  9. Van Horn, D. J., Myers, M. G., Jr., and Backer, J. M. (1994) J. Biol. Chem. 269, 29-32 [Abstract/Free Full Text]
  10. Dalphin, M. E., Brown, C. M., Stockwell, P. A., and Tate, W. P. (1996) Nucleic Acids Res. 24, 216-218 [Abstract/Free Full Text]
  11. Sun, X. J., Wang, L.-M., Zhang, Y., Yenush, L., Myers, M. G., Jr., Glasheen, E., Lane, W. S., Pierce, J. H., and White, M. F. (1995) Nature 377, 173-177 [CrossRef][Medline] [Order article via Infotrieve]
  12. Gibson, T. J., Hyvönen, M., Musacchio, A., Saraste, M., and Birney, E. (1994) Trends Biochem. 19, 349-353 [CrossRef][Medline] [Order article via Infotrieve]
  13. Myers, M. G., Jr., Grammer, T. C., Brooks, J., Glasheen, E. M., Wang, L.-M., Sun, X. J., Blenis, J., Pierce, J. H., and White, M. F. (1995) J. Biol. Chem. 270, 11715-11718 [Abstract/Free Full Text]
  14. Voliovitch, H., Schindler, D. G., Hadari, Y. R., Taylor, S. I., Accili, D., and Zick, Y. (1995) J. Biol. Chem. 270, 18083-18087 [Abstract/Free Full Text]
  15. Yenush, L., Makati, K. J., Smith-Hall, J., Ishibashi, O., Myers, M. G., Jr., and White, M. F. (1996) J. Biol. Chem. 271, 24300-24306 [Abstract/Free Full Text]
  16. Wolf, G., Trüb, T., Ottinger, E., Groninga, L., Lynch, A., White, M. F., Miyazaki, M., Lee, J., and Shoelson, S. E. (1995) J. Biol. Chem. 270, 27407-27410 [Abstract/Free Full Text]
  17. Eck, M. J., Dhe-Paganon, S., Trüb, T., Nolte, R. T., and Shoelson, S. E. (1996) Cell 85, 695-705 [Medline] [Order article via Infotrieve]
  18. Gustafson, T. A., He, W., Craparo, A., Schaub, C. D., and O'Neill, T. J. (1995) Mol. Cell. Biol. 15, 2500-2508 [Abstract]
  19. Sawka-Verhelle, D., Tartare-Deckert, S., White, M. F., and Van Obberghen, E. (1996) J. Biol. Chem. 271, 5980-5983 [Abstract/Free Full Text]
  20. He, W., Craparo, A., Zhu, Y., O'Neill, T. J., Wang, L.-M., Pierce, J. H., and Gustafson, T. A. (1996) J. Biol. Chem. 271, 11641-11645 [Abstract/Free Full Text]
  21. Songyang, Z., Shoelson, S. E., Chaudhuri, M., Gish, G., Pawson, T., Haser, W. G., King, F., Roberts, T., Ratnofsky, S., Lechleider, R. J., Neel, B. G., Birge, R. B., Fajardo, J. E., Chou, M. M., Hanafusa, H., Schaffhausen, B., and Cantley, L. C. (1993) Cell 72, 767-778 [Medline] [Order article via Infotrieve]
  22. Songyang, Z., Shoelson, S. E., McGlade, J., Olivier, P., Pawson, T., Bustelo, X. R., Barbacid, M., Sabe, H., Hanafusa, H., Yi, T., Ren, R., Baltimore, D., Ratnofsky, S., Feldman, R. A., and Cantley, L. C. (1994) Mol. Cell. Biol. 14, 2777-2785 [Abstract]
  23. Herbst, J. J., Andrews, G., Contillo, L., Lamphere, L., Gardner, J., Lienhard, G. E., and Gibbs, E. M. (1994) Biochemistry 33, 9376-9381 [Medline] [Order article via Infotrieve]
  24. Patschinsky, T., Hunter, T., Esch, F. S., Cooper, J. A., and Sefton, B. M. (1982) Proc. Natl. Acad. Sci. U. S. A. 79, 973-977 [Abstract]
  25. Altschul, S. F., Gish, W., Miller, W., Myers, E. W., and Lipman, D. J. (1990) J. Mol. Biol. 215, 403-410 [CrossRef][Medline] [Order article via Infotrieve]

©1997 by The American Society for Biochemistry and Molecular Biology, Inc.